BRTX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BR

Mkt Cap

$2.1M

Volume

20.91K

Next Earnings

November 11th

Loading chart

BR

BRTXBioRestorative Therapies, Inc. Common Stock (NV)

BRTX

Pay with—

Available Balance0.00

BR

Mkt Cap

$2.1M

Volume

20.91K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline DataBioRestorative Therapies announced completion of dosing in its Phase 2 clinical trial for BRTX-100, treating 99 patients with chronic lumbar disc disease. The randomized, double-blind, sham-controlled study has advanced to blinded follow-up with topline safety and efficacy data expected in Q2 2027. The company received FDA alignment on Phase 3 development pathway following a Type B meeting, with no clinical safety concerns raised.GlobeNewswire Inc. · May 26, 2026

BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticalsBioRestorative Therapies presented preclinical data at ISCT 2026 demonstrating that extracellular vesicles derived from different mesenchymal stem cell sources exhibit distinct protein signatures and functional properties. The findings support development of targeted exosome-based formulations for regenerative and aesthetic applications, with implications for the company's BioCosmeceutical platform spanning skin rejuvenation, wound repair, and hair health applications.GlobeNewswire Inc. · May 13, 2026

BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026BioRestorative Therapies will participate in the Be+Well Beauty and Wellness Show (March 8-10, 2026) to expand commercialization of its BioCosmeceutical platform. The company's commercial leadership team will engage with industry partners and distributors to discuss product adoption and deployment of regenerative skincare technologies. BioRestorative positions itself as a differentiated biotech player in the emerging regenerative aesthetics market, leveraging its cGMP-compliant manufacturing and scientific infrastructure.GlobeNewswire Inc. · Mar 5, 2026

BioRestorative Announces Closing of $5.0 Million Public OfferingBioRestorative Therapies, Inc. (NASDAQ:BRTX) announced the closing of a public offering of 14,285,715 shares and accompanying warrants at $0.35 per share, raising approximately $5.0 million in gross proceeds. The company plans to use the funds for clinical trials of BRTX-100 (a stem cell therapy for disc/spine disease), pre-clinical research on its ThermoStem Program (for metabolic disorders), development of its commercial biocosmeceuticals platform, and general corporate purposes.GlobeNewswire Inc. · Feb 14, 2026

BioRestorative Announces Pricing of $5.0 Million Public OfferingBioRestorative Therapies (NASDAQ:BRTX) announced the pricing of a public offering of approximately 14.3 million shares and warrants at $0.35 per share, expected to raise $5.0 million in gross proceeds. The company plans to use the funds for clinical trials of BRTX-100, pre-clinical research for its ThermoStem Program, development of its biocosmeceuticals platform, and general corporate purposes.GlobeNewswire Inc. · Feb 12, 2026

Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsightDelveInsight released a comprehensive analysis of the chronic and acute pain clinical trial pipeline, identifying 150+ active companies developing 200+ pipeline drugs across various clinical stages. The report highlights a shift toward non-opioid, targeted, and multimodal approaches due to growing concerns about opioid dependence. Recent developments include FDA orphan drug designation for Adolore BioTherapeutics' gene therapy, positive Phase IIb results for Dogwood Therapeutics' Halneuron, and Phase III publication of Vertanical's VER-01 for chronic low back pain.GlobeNewswire Inc. · Jan 28, 2026

BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc DiseaseBioRestorative Therapies has been granted a Type B meeting with the FDA to discuss an accelerated Biologics License Application approval pathway for BRTX-100, a stem cell-based treatment for chronic lumbar disc disease, with plans to request an expedited Phase 3 trial timeline.GlobeNewswire Inc. · Nov 17, 2025

BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc DiseaseBioRestorative Therapies presented promising preliminary data from its ongoing Phase 2 clinical trial of BRTX-100, an autologous stem cell therapy for chronic lumbar disc disease. The data showed significant improvements in pain and function for a majority of subjects, with a favorable safety profile.GlobeNewswire Inc. · Jun 13, 2025

BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline UpdateBioRestorative Therapies, Inc. announced that it has changed the time for its previously announced webcasted conference call to discuss its pipeline update. The company will now host the call at 10:30am EST on Thursday, February 27, 2025.GlobeNewswire Inc. · Feb 27, 2025

BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program– Adds to comprehensive patent portfolio underlying novel ThermoStem® technology platform –GlobeNewswire Inc. · Jun 27, 2024

to start trading

BR

BRTXBioRestorative Therapies, Inc. Common Stock (NV)

BRTX

Pay with—

Available Balance0.00

Your PositionYou don't own any BRTX yet.

Related Tickers

Earnings